GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Float Percentage Of Total Shares Outstanding

Catalyst Pharmaceuticals (FRA:CN2) Float Percentage Of Total Shares Outstanding : 80.44% (As of May. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's float shares is 95.02 Mil. Catalyst Pharmaceuticals's total shares outstanding is 118.12 Mil. Catalyst Pharmaceuticals's float percentage of total shares outstanding is 80.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Catalyst Pharmaceuticals's Institutional Ownership is 51.60%.

Catalyst Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Catalyst Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=95.02/118.12
=80.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals (FRA:CN2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
BEAM AGIO SNDX FUSN HRMY DNA INBX ZLAB SANA RXRX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
CPRX:USA
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Website
https://www.catalystpharma.com
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (FRA:CN2) Headlines

No Headlines